A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
← catalyst calendarNCT05926765 · readout ≤ 314 d
Sponsored by MeiraGTx, LLC (industry) · MGTX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
290actual
Sites
33
Countries
Canada, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-13 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Interventions
- Genetic: AAV2-hAQP1 Concentration 1
- Genetic: AAV2-hAQP1 Concentration 2
- Other: Placebo
- Genetic: AAV2-hAQP1 Concentration 3
- Genetic: AAV2-hAQP1 Concentration 4
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Month 12 in Xerostomia-specific Questionnaire (XQ) Total Score
measured 12 months
Permalink · MGTX's whole pipeline · Catalyst calendar · Every registered study · What changed